eFFECTOR Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EFTR research report →
Range $1 – $10
Price Chart
About the company
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK.
- CEO
- Craig R. Jalbert
- IPO
- 2021
- Employees
- 14
- HQ
- Solana Beach, CA, US
Get TickerSpark's AI analysis on EFTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $941
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3771.56%
- ROIC
- -221.30%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-111,000-103.2%
- Op Income
- $-33,844,000
- Net Income
- $-35,811,000-177.0%
- EPS
- $-16.37-108.5%
- OCF Growth
- -14.1%
- FCF Growth
- -13.6%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.48
- RSI (14)
- 44
- Avg Volume
- 2.18K
No earnings-call transcripts are available for EFTR yet.
- Free Float
- 99.2%
- Shares Outstanding
- 4.70M
- Float Shares
- 4.67M
of shares held by institutions
3 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Abingworth Llp | 4.82M | 0 |
| Oup Management Co., LLC | 1.03M | 0 |
| Evolution Capital Management LLC | 527.88K | 0 |
| Resolute Financial, LLC | 31.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 24 | Loewy Caroline M | other | 800 |
| Jun 13, 24 | Klencke Barbara | other | 800 |
| Jun 13, 24 | Ehrlich Christopher B | other | 800 |
| Jun 13, 24 | Harrington-Smith Kristen | other | 800 |
| Jun 13, 24 | Gallagher Brian M. Jr. | other | 800 |
| Jun 13, 24 | Bhatt Elizabeth | other | 800 |
| May 15, 24 | Byrnes Michael | other | 1,387 |
| May 15, 24 | WORLAND STEPHEN T | other | 1,806 |
| Feb 19, 24 | Loewy Caroline M | other | 2,000 |
| Feb 19, 24 | Bhatt Elizabeth | other | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EFTR coverage
Recent articles, reports, and earnings notes.
No research on EFTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EFTR report →Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
defenseworld.net · Jan 6
eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast
defenseworld.net · Nov 22
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
newsfilecorp.com · Dec 4
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
investorplace.com · Jul 15
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
globenewswire.com · Jun 24
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
globenewswire.com · May 20
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
investorplace.com · May 9
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com · May 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.